-
Shanghai Lu Xiangyi strengthened overseas cooperation, and 150 sets of TD5 centrifuges were sent to Belarus
Time of Update: 2022-10-25
150 TD5 centrifuges were loaded into trucks and sent to Belarus As a professional manufacturer of centrifuge equipment, Shanghai Lu Xiangyi not only meets the domestic market demand, but also constantly explores overseas markets, and sends laboratory scientific research instruments and medical centrifuge equipment to overseas to meet the needs of overseas markets.
-
The market space in the field of anti-cancer treatment is vast, and this pharmaceutical company focusing on CAR-T technology intends to be listed on the science and technology innovation board!
Time of Update: 2022-10-25
, of which the HR001 drug research and development for the treatment of "relapsed/refractory B-cell non-Hodgkin lymphoma (r/rB-NHL)" has made rapid progress, has entered the phase II clinical registration link, and is expected to submit a new drug marketing application in 2023.
-
The pharmaceutical company has invested heavily in an innovative drug, and its R&D pipeline is becoming increasingly rich
Time of Update: 2022-10-20
In recent years, in order to comply with the development of the industry, CSPC Group has been continuously expanding and optimizing its own pipeline through independent research and development, acquisition, and stake in new companies.
-
The third quarterly report disclosure kicked off, and another pharmaceutical company achieved growth
Time of Update: 2022-10-20
442 billion yuan in the first three quarters, a year-on-year increase of 55%-70%; Li Pharmaceutical expects its net profit to increase by 52.
442 billion yuan in the first three quarters, a year-on-year increase of 55%-70%; Li Pharmaceutical expects its net profit to increase by 52.
-
Next month, the multinational pharmaceutical company's big acquisition of more than $10 billion will land!
Time of Update: 2022-10-14
At present, the global pharmaceutical market is surging, and it has become very common for multinational pharmaceutical companies to extend or expand product lines, cut costs, and optimize organizational structures through layoffs, investments, acquisitions, etc.
-
Another pharmaceutical company is going to be spun off and listed, and plans to raise 2.47 billion yuan
Time of Update: 2022-10-14
It is understood that Xuanzhu Bio is an innovative pharmaceutical enterprise focusing on major diseases such as digestion, oncology and non-alcoholic steatohepatitis, and is also a subsidiary of Sihuan Pharmaceutical, a Hong Kong-listed company.
-
Another pharmaceutical company has passed the on-site inspection of the US FDA and achieved new results in its going out strategy
Time of Update: 2022-10-13
The U. S. Food and Drug Administration (FDA) is the world's most stringent regulatory authority for the inspection and supervision of pharmaceutical products, and its recognition is equivalent to obt
-
The multinational pharmaceutical company is constantly initiating cooperation to accelerate the development of new drugs
Time of Update: 2022-10-13
At that time, Sanofi will take over all new drug research as well as development and commercialization, and will pay miRecule an advance payment of $30 million and recent milestones.
-
The multinational pharmaceutical company has approved the listing of a number of new drugs in China
Time of Update: 2022-10-03
For example, recently, the website of the Drug Evaluation Center (CDE) of the State Food and Drug Administration showed that the application for the listing of Pfizer JAK3 inhibitor litecotinib capsules was accepted for the treatment of adolescents aged 12 and over and adults alopecia areata.
-
This pharmaceutical company has blossomed in the field of new oncology drugs, and another new drug has been approved clinically!
Time of Update: 2022-10-02
It is worth noting that in addition to SHR-A2102 injection, Hengrui Pharmaceutical recently issued an announcement that it received the "Drug Clinical Trial Approval Notice" approved by the State Food and Drug Administration on HRS-6209 capsules, and will carry out clinical trials in the near future.
-
This pharmaceutical machine company has been investigated by the institution, and the company's products have a strong competitive advantage
Time of Update: 2022-10-02
According to reports, the main business of Tailin Biology is the research and development, manufacturing and sales of pharmaceutical equipment such as microbial detection and control technology system products and organic matter analysis instruments.
-
In order to be more streamlined, Novartis plans to lay off thousands more people and close some factories
Time of Update: 2022-10-01
Since the beginning of this year, Novartis, a leading multinational pharmaceutical company, has made continuous moves, first announcing the adjustment of the company's global business framework, planning to lay off 8,000 employees, and then integrating the two business units of pharmaceuticals and oncology into one innovative drug department, while merging the technology operations, customers and technical departments.
-
In the first half of the year, domestic pharmaceutical companies with R&D investment of more than 1 billion yuan have a variety of potential first-in-class
Time of Update: 2022-10-01
According to reports, JS004 is the world's first recombinant humanized anti-BTLA monoclonal antibody specifically targeting B and T lymphocyte attenuation factor (BTLA) that has entered the clinical development stage of the company's independent research and development.
-
Today, another new pharmaceutical stock will be listed on the GEM!
Time of Update: 2022-10-01
It is worth mentioning that in addition to the external lotion of gynecology, Enwei Pharmaceutical has not disconnected the dosage forms such as ointments, suppositories, effervescent tablets and disinfection products such as bacteriostatic lotion, and intends to develop gynecological internal medicine series products in independent research and development, joint research and development, purchase of varieties and other ways, and constantly maintain and further enhance the company's advantages in the field of domestic gynecological products.
-
In the 100 billion market, this pharmaceutical company with a large number of new drugs is accelerating the grabbing of food
Time of Update: 2022-09-30
In fact, in recent years, Yangtze River Pharmaceutical and its subsidiaries are still increasing the research and development of nervous system drugs, in addition to the advantages of pain relief, mental stability, local anesthesia, but also expanded to other subcategories.
-
Two chemical drugs have been approved one after another! The landing of pipeline products of the pharmaceutical company is gradually being cashed in
Time of Update: 2022-09-14
On September 6, Tasly announced that jiangsu Diyi, a wholly-owned subsidiary of the company, recently received the "Drug Registration Certificate" approved and issued by the State Drug Administration on bortezomib for injection.
-
This traditional Chinese medicine company issued 19 announcements in one day, related to the semi-annual report, the departure of executives, etc.
Time of Update: 2022-09-09
1576 million, and the financing balance decreased ; According to information from the Shenzhen Stock Exchange, on August 26, *ST Bikang issued 19 announcements in succession, which were related to the interim report performance and the resignation of executives .
-
Local pharmaceutical companies have expanded production capacity, and this company has broken restrictions to double its revenue
Time of Update: 2022-09-09
Judging from the commercialized product line, up to now, Henlius has a total of 5 products approved for marketing, namely rituximab (Hanlikang), trastuzumab (Hanquyou), adalimumab Monoclonal antibody (Handayuan), bevacizumab (Hambetai) 4 biosimilars, and innovative drug PD-1 inhibitor slulimumab (Hans-shaped) .
-
In order to enhance competitiveness, this traditional Chinese medicine formula granule company has increased capital and shares!
Time of Update: 2022-09-09
For example, on June 29 this year, Yibai Pharmaceutical announced that, by consensus, the company plans to jointly increase the capital of Yibai Formula Granules, a wholly-owned subsidiary of the company, with the Guizhou Agricultural Development Fund to invest in the construction of the company's entire industry chain project of traditional Chinese medicine formula granules .
-
The pharmaceutical company's innovative drugs have reported good news one after another. In the first half of the year, the company's R&D investment increased by 22.77% year-on-year.
Time of Update: 2022-09-08
On the evening of August 26, Fosun Pharma announced that its holding subsidiary Fuhong Henlius’ HLX60 (recombinant anti-GARP humanized monoclonal antibody injection) combined with slulimumab injection (Hans-shaped) was used for Advanced/metastatic solid tumor therapy approved for clinical trials in Australia .
